Product Overview
FOXO4-DRI is a senolytic research peptide built with a D-retro-inverso (DRI) modification, which improves its stability and cell permeability.
It targets the interaction between the FOXO4 protein and the tumor suppressor p53. Senescent cells depend on this binding to avoid programmed cell death. By occupying the FOXO4 interface, FOXO4-DRI releases p53, and research has examined how this leads to apoptosis in senescent cells, where FOXO4 is overexpressed.
The peptide gained attention through the work of Baar et al. (Cell, 2017) and has been studied in naturally aged and progeroid mouse models. It is used mainly in cellular senescence research.
Important Note
This product is not approved for human consumption, medical or veterinary use, or diagnostic purposes. It is supplied for laboratory research only and should be handled by qualified professionals in a controlled research setting.
Specifications
| Specification | Detail |
|---|---|
| Peptide Type | D-retro-inverso (DRI) modified peptide |
| Vial Content (labeled) | 10mg |
| Measured Content | 10.34 mg |
| Measured Purity | 98.161% (HPLC) |
| Form | Lyophilized powder |
| Storage | Store below –20°C. Keep away from light. |
| Vial | Clear borosilicate glass, butyl rubber stopper, aluminum crimp closure |
| Lot Number | TGC-FOX-20260723 |
| Test Date | 04 Aug 2026 |
| Testing Lab | Janoshik |
| Lab Report | Janoshik #211875 (Verification Key: 3ASZ1DZWNDIX) |
| Endotoxin Report | Janoshik #211876 |
| Heavy Metals Report | Janoshik #211877 |
Features & Properties
- D-retro-inverso (DRI) modified peptide with improved stability and permeability
- Studied for its disruption of the FOXO4–p53 protein interaction
- Examined for its role in releasing p53 and inducing apoptosis in senescent cells
- Studied in naturally aged and progeroid mouse models
- Used in senolytic and cellular-senescence research
- Supplied as a lyophilized powder for stability during storage and transport
Storage & Stability
- Store the lyophilized powder at –20°C, where it remains stable for up to 24 months
- Avoid repeated freeze–thaw cycles
- Protect from light and moisture at all times
Usage Restrictions
- For laboratory research use only
- Not approved for human consumption, medical or veterinary use, or diagnostic purposes
- Handling should be carried out by qualified professionals in controlled research settings
- Store securely and keep out of reach of children
- Do not handle during pregnancy or breastfeeding
Frequently Asked Questions
Q1. What does each vial contain?
Each vial is labeled at 10mg of FOXO4-DRI as a sterile lyophilized powder. The Janoshik test for this lot measured 10.34 mg.
Q2. What does the product look like?
A fine white to off-white powder that sits at the base of the vial.
Q3. How should it be stored?
Keep it at –20°C, away from light and moisture. Stored this way, it remains stable for up to 24 months.
Q4. Is it sterile?
It is manufactured and sealed under sterile laboratory conditions. Standard sterile handling still applies in the lab.
Q5. Is this product for human use?
No. It is intended for laboratory research only and is not approved for medical or veterinary use.
Q6. Has this lot been third-party tested?
Yes. Lot TGC-FOX-20260723 was tested by Janoshik on 04 Aug 2026 (Report #211875), with a measured purity of 98.161% and a measured content of 10.34 mg. Separate endotoxin (Report #211876) and heavy metals (Report #211877) analyses are also available. All three reports can be viewed through the COA / Testing links on this page.
Q7. What is the vial packaging?
A clear borosilicate glass vial sealed with a butyl rubber stopper and an aluminum crimp closure.
Q8. Is the product stable during shipping?
The lyophilized form holds up under standard shipping conditions. Move it to –20°C storage as soon as it arrives.
Q9. Who can handle this product?
Only qualified laboratory researchers trained in peptide handling and using proper protective equipment.
